Maud A.W. Hermans

The JAK1/JAK2‐ inhibitor ruxolitinib inhibits mast cell degranulation and cytokine release

Maud A.W. Hermans, Benjamin Schrijver, Conny C.P.A. van Holten‐Neelen et al. · Clinical & Experimental Allergy · 2018 · 60 citations · Full text

The value of the Mortality in Emergency Department Sepsis (MEDS) score, C reactive protein and lactate in predicting 28-day mortality of sepsis in a Dutch emergency department

Maud A.W. Hermans, Pieter Leffers, Lucres M. C. Jansen et al. · Emergency Medicine Journal · 2011 · 39 citations

Mast cell leukemia: clinical and molecular features and survival outcomes of patients in the ECNM Registry

Vanessa E. Kennedy, Cecelia Perkins, Andreas Reiter et al. · Blood Advances · 2022 · 38 citations · Full text

Systemic mastocytosis: A cohort study on clinical characteristics of 136 patients in a large tertiary centre

Maud A.W. Hermans, Mark J.A. Rietveld, Jan A. M. van Laar et al. · European Journal of Internal Medicine · 2016 · 37 citations

Large Tertiary Centre, Allergy, Mast Cell Disorder +4

Predictive accuracy and feasibility of risk stratification scores for 28-day mortality of patients with sepsis in an emergency department

Michelle J.M. Hilderink, Asselina A. Roest, Maud A.W. Hermans et al. · European Journal of Emergency Medicine · 2014 · 34 citations